O-1812 is an eicosanoid derivative related to anandamide that acts as a potent and highly selective agonist for the cannabinoid receptorCB1, with a Ki of 3.4nM at CB1 and 3870nM at CB2. Unlike most related compounds, O-1812 is metabolically stable against rapid breakdown by enzymes, and produces a cannabinoid-like discriminative effect in rats, which is similar but not identical to that produced by cannabinoid drugs of other chemical classes.
^Di Marzo V et al. (February 2001). "Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor "hybrid" ligands". Biochemical and Biophysical Research Communications281 (2): 444–51. doi:10.1006/bbrc.2001.4354. PMID11181068.CS1 maint: Explicit use of et al. (link)
^Baskfield CY, Martin BR, Wiley JL (April 2004). "Differential effects of delta9-tetrahydrocannabinol and methanandamide in CB1 knockout and wild-type mice". The Journal of Pharmacology and Experimental Therapeutics309 (1): 86–91. doi:10.1124/jpet.103.055376. PMID14718593.
^Wiley JL et al. (August 2004). "A comparison of the discriminative stimulus effects of delta(9)-tetrahydrocannabinol and O-1812, a potent and metabolically stable anandamide analog, in rats". Experimental and Clinical Psychopharmacology12 (3): 173–9. doi:10.1037/1064-12220.127.116.11. PMID15301634.CS1 maint: Explicit use of et al. (link)
^Wiley JL, Smith FL, Razdan RK, Dewey WL (March 2005). "Task specificity of cross-tolerance between Delta9-tetrahydrocannabinol and anandamide analogs in mice". European Journal of Pharmacology510 (1-2): 59–68. doi:10.1016/j.ejphar.2005.01.006. PMID15740725.